TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35079918
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) with red (λ 660 nm) and infra-red laser therapy (λ 808 nm) applied immediately and 3 and 7 days after surgery.
Study: 33653121
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg over 40 minutes)
Study: 33080378
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) control group
Study: 34949135
Drug: sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: sham treatment
Study: 34369680
Drug: Control (medication)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (medication)
Study: 34498056
Drug: Filgotinib (FIL)
Normalized name: Nilotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgotinib (FIL) 200 mg once daily for 12 weeks
Study: 32535601
Drug: Combined physical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined physical movement activity and multifaceted cognitive training (24 sessions, twice a week)
Study: 35965825
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion
Study: 35935625
Drug: Dabigatran 110
Normalized name: dabigatran 110 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 110 mg
Study: 39536780
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment)
Study: 32005012
Drug: Atorvastatin (ATO)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (ATO) 20 mg daily
Study: 33346899
Drug: Surface treatment
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surface treatment group (intraoperative spraying and drug-soaked gauze covering the wound combined with local injection into the articular cavity)
Study: 34551495
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 7 ml/kg (group V3)
Study: 32150549
Drug: Weekly healthy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly healthy lean donor FMT capsules for 6 weeks
Study: 32895353
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 milligrams orally daily for 6 months
Study: 33275769
Drug: Short-term maintenance
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term maintenance rituximab (375 mg/m2 every 2 months, 4 administrations; n = 82)
Study: 33275769
Drug: Long-term maintenance
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term maintenance rituximab (375 mg/m2 every 2 months, up to 5 years; n = 83)
Study: 38252515
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy
Study: 36317847
Drug: Posterior-stabilized (PS)
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior-stabilized (PS) implant
Study: 36317847
Drug: Medial-stabilized (MS)
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medial-stabilized (MS) implant
Study: 32851588
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of sleep medication
Study: 32289325
Drug: Low Energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Energy Density (LED) preload: 1.00 kcal/g; 100 kcal
Study: 35957963
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture combined with medication
Study: 36063821
Drug: Asundexian 20
Normalized name: Asundexian
DrugBank: Asundexian (DB19088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asundexian 20 mg
Study: 38977653
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy
Study: 33358164
Drug: Zn amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zn amino acid complex (ZA; 40 mg/kg DM)
Study: 37675038
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) monotherapy
Study: 35778479
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of coconut oil/day
Study: 32169019
Drug: Oxytocin vaginal
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin vaginal gel (400 IU, n=48)
Study: 32017322
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (40 min, twice a week for 12 months)
Study: 35451858
Drug: galcanezumab 120
Normalized name: Galcanezumab 120 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: galcanezumab 120 mg/month (following a 240 mg loading dose)
Study: 35701185
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets 3.5 mg/kg
Study: 34650034
Drug: Toripalimab plus
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab plus chemotherapy (carboplatin and pemetrexed)
Study: 32713702
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (LGH, MGH, HGH)
Study: 36882804
Drug: Platelet-Rich Plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-Rich Plasma (PRP) injection
Study: 32310283
Drug: Adherent patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherent patients to PAP therapy
Study: 34431926
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection technique without aspiration
Study: 35575611
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg/d)
Study: 35197354
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg vaginal micronised progesterone supplemented with 50 mg intramuscular progesterone per day
Study: 33338464
Drug: Vasoactive treatments
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive treatments
Study: 36597186
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment
Study: 36192386
Drug: Sinovac-CoronaVac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinovac-CoronaVac vaccine
Study: 36151280
Drug: Traditional syringe
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional syringe infiltration (flow rate of 1.8 ml/60 sec)
Study: 35577100
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion
Study: 35674591
Drug: Bolus insulin
Normalized name: bolus insulin pump, 200 unit 2 unit MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus insulin
Study: 34119067
Drug: Cetuximab with
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab with chemotherapy
Study: 38814736
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT)
Study: 35352593
Drug: tolcapone 600
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tolcapone 600 mg/day
Study: 34402044
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen plus mouthpiece (50 l.min-1 + 15 l.min-1)
Study: 33145642
Drug: Otelixizumab 18
Normalized name: Otelixizumab
DrugBank: Otelixizumab (DB05496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otelixizumab 18 mg
Study: 34698342
Drug: Free distribution
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free distribution of oral rehydration salts (ORS) via home deliveries prior to diarrhoea onset
Study: 32822676
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment vs. full resection
Study: 38815173
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU)
Study: 35524794
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA)
Study: 35573994
Drug: Daily somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily somatropin 0.05 mg/kg/day
Study: 35588754
Drug: Mixed vaccine
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed vaccine regimen
Study: 35788416
Drug: SC CAS+IMD
Normalized name: CA-170
DrugBank: CA-170 (DB15772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC CAS+IMD 1200 mg
Study: 33499521
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 oral supplement (OS) for 10 weeks
Study: 34738278
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia
Study: 39367366
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual
Study: 34651260
Drug: Intrauterine infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine infusion of 0.5 ml PRP 48 h before embryo transfer
Study: 34763071
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin degludec (IDeg)
Study: 34763071
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) with aspart
Study: 34144995
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure lowering therapy
Study: 33513546
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose (0.24 mL of 24% oral sucrose plus non-nutritive sucking)
Study: 39216095
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment
Study: 38781664
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg
Study: 33450486
Drug: Intermittent low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermittent low-dose esomeprazole
Study: 35109430
Drug: Mentalizing Imagery
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalizing Imagery Therapy (MIT)
Study: 36362815
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of colon-targeted microencapsulated sodium butyrate combined with probiotic Lactobacillus strains (L. rhamnosus and L. acidophilus) and Bifidobacterium strains (B. longum, B. bifidum, B. lactis), and 64 mg of prebiotic scFOS
Study: 36383742
Drug: Oral benzodiazepines
Normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral benzodiazepines (considered as a continuous predictor)
Study: 34992553
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (Music therapy and Music listening)
Study: 34767149
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rectal diclofenac 100 mg and epinephrine spray (0.02%) on duodenal papilla (group A)
Study: 34767149
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rectal diclofenac 100 mg and saline spray on duodenal papilla (group B)
Study: 32770384
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (GnRHant) alone
Study: 32770384
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (GnRHant) + placebo
Study: 39453735
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg twice daily
Study: 39171416
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT)
Study: 36172933
Drug: LDL-C 70
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C 70 to 100 mg/dL
Study: 33612359
Drug: AP overlay
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP overlay with Gel pad
Study: 32648861
Drug: Coconut oil
Normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut oil (1 tablespoon or 12 mL daily)
Study: 36889611
Drug: Therapeutic-dose anticoagulation
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic-dose anticoagulation (therapeutic-dose enoxaparin and therapeutic-dose apixaban)
Study: 33611431
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy alone (arm B)
Study: 34486986
Drug: Istradefylline 20
Normalized name: istradefylline 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istradefylline 20 mg/day
Study: 34337072
Drug: Insulin titration
Normalized name: INSULIN TITRATION ORAL INHL KIT 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin titration goal of FBG≤6.1 mmol/L
Study: 38580424
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg once daily
Study: 32535812
Drug: Selatinib (suspension)
Normalized name: Telatinib
DrugBank: Telatinib (DB15393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selatinib (suspension)
Study: 35678594
Drug: S1 maintenance
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: S1 maintenance therapy (S1-MT)
Study: 34028656
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy plus Amitriptyline
Study: 33745627
Drug: Caffeine mouth
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine mouth rinse (300 mg, 1.2%)
Study: 34780207
Drug: Weekly session
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly session frequency
Study: 38846918
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment
Study: 37592272
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (FCM)
Study: 36495879
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine 3.6 mg/kg
Study: 32583773
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment
Study: 34898074
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E soft capsules, 100 mg bid for 12 weeks
Study: 36344978
Drug: Multifactorial intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intensive treatment
Study: 33658007
Drug: Goal-directed hemodynamic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed hemodynamic management (maintaining stroke volume variation < 6%, cardiac index 3.0-4.0 L/min/m2, mean arterial pressure > 95 mmHg with crystalloid fluids and infusion of dobutamine and/or norepinephrine)
Study: 36029412
Drug: ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab 10 mg/kg (ipi10)
Study: 32324651
Drug: Adalimumab (ADL)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADL) treatment
Study: 33222559
Drug: Baricitinib 4-mg
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4-mg
Study: 38211393
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg/day
Study: 36056908
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (PSL)
Study: 38580558
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K Antagonists (VKA)
Study: 32907904
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g cholestyramine (CTM) powder monotherapy
Study: 33031335
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) intervention for 12 weeks
Study: 36151961
Drug: Sublingual Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual Misoprostol alone
Study: 36151961
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Foley's transcervical catheter and sublingual Misoprostol
Study: 35466101
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (NAC and nutraceuticals)
Study: 33470329
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) - aspirin and ticagrelor
Study: 32452344
Drug: Baricitinib 4-mg
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4-mg once daily
Study: 34718468
Drug: Bamlanivimab and
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bamlanivimab and etesevimab (700/1400 mg)
Study: 32797376
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) followed by chemoradiotherapy (CRT) - TPF arm
Study: 32797376
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) followed by chemoradiotherapy (CRT) - TPF or PF arm
Study: 32544575
Drug: Conventionally fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally fractionated radiation therapy (CFRT)
Study: 36259089
Drug: 3 +
Normalized name: D3 + K2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 + Q12W (fixed dosing regimen with injections every 12 weeks)
Study: 35577602
Drug: 15 U
Normalized name: vitamin E 15 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 U Ultra Rapid Lispro (URLi) administered subcutaneously into the abdomen
Study: 32891191
Drug: GBS6 without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GBS6 without AlPO4 10 μg
Study: 34049908
Drug: Polyurethane-covered implants
Normalized name: polyurethane-62
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyurethane-covered implants
Study: 34254980
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU, n=152)
Study: 32703038
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg policosanol (group B)
Study: 37490604
Drug: Oral sulfate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulfate solution (OSS)
Study: 34340595
Drug: Urate level
Normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Urate level increase (1 mg/dL)
Study: 36177835
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment
Study: 35450527
Drug: Ultramicronized PEA-LUT
Normalized name: Pea
DrugBank: Pea (DB10551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultramicronized PEA-LUT 770 mg plus olfactory training
Study: 32696178
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation (3 g/day for 8 weeks)
Study: 36571770
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 1200 mg intravenously every 2 weeks
Study: 39671272
Drug: Camrelizumab plus
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab plus chemotherapy
Study: 33888139
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g every 8 hours